BRISBANE, Calif., Jan. 4, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will report unaudited fourth quarter 2011 revenue related to sales of Esbriet® (pirfenidone) in Germany, as well as other metrics related to the Esbriet launch, prior to the open of the U.S. markets on Thursday, January 5, 2012. A live conference call and webcast will be hosted by InterMune at 8:30 a.m. Eastern time that same day. InterMune also plans to report additional efficacy and survival data from the ongoing RECAP extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The company will review its plans to gain reimbursement for Esbriet across Europe and an expert in German drug reimbursement law will answer questions on the call. Additionally, the company will update its expense guidance for 2011 and will provide forward-looking expense guidance for the full year 2012.
Interested investors and others may participate in the conference call by dialing 888-567-5125 (U.S.) or 706-643-9223 (international), conference ID# 40200495. To access the live webcast of the call, please log on to the company’s website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available on the company’s website approximately three hours after the call and will remain available until the company’s next earnings call.
A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 855-859-2056 (U.S.) or 404-537-3406 (international), and entering the conference ID# 40200495.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and fibrotic diseases. In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved worldwide for IPF, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®. InterMune’s research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
SOURCE InterMune, Inc.
